TY - JOUR
T1 - Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated
T2 - insights from a case-control study targeting the pediatric population
AU - Damiani, G.
AU - Finelli, R.
AU - Kridin, K.
AU - Pacifico, A.
AU - Bragazzi, N. L.
AU - Malagoli, P.
AU - Fabbrocini, G.
AU - Bonifazi, E.
AU - Mazzotta, F.
AU - Lovati, C.
AU - Savoia, P.
AU - Gironi, L. C.
AU - Morello, M.
AU - Davidson, T.
AU - Watad, A.
AU - Goker, F.
AU - Mortellaro, C.
AU - Del Fabbro, M.
N1 - Publisher Copyright:
© 2022 Verduci Editore s.r.l. All rights reserved.
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated. PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire. RESULTS: DFI index did not differ significantly between both subgroups (p=0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p=0.59) and itch-VAS (p=0.16). CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.
AB - OBJECTIVE: COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated. PATIENTS AND METHODS: This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire. RESULTS: DFI index did not differ significantly between both subgroups (p=0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p=0.59) and itch-VAS (p=0.16). CONCLUSIONS: COVID-19 toes, a transitory dermatosis, exerted a similar impact/perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.
KW - COVID-19 toes
KW - Chilblain-like lesions
KW - Dermatitis family impact
KW - Pediatrics
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85145344840&partnerID=8YFLogxK
U2 - 10.26355/EURREV_202212_30798
DO - 10.26355/EURREV_202212_30798
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36591876
AN - SCOPUS:85145344840
SN - 1128-3602
VL - 26
SP - 87
EP - 93
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
IS - 3
ER -
